Also found in: Dictionary, Thesaurus, Wikipedia.


Ezetrol (UK), Zetia

Pharmacologic class: Cholesterol absorption inhibitor

Therapeutic class: Antihyperlipidemic

Pregnancy risk category C


Inhibits cholesterol absorption in the intestine, decreasing intestinal delivery of cholesterol to the liver and increasing systemic cholesterol clearance. Net effect is decreased serum cholesterol level.


Tablets: 10 mg

Indications and dosages

Adjunct to diet to reduce elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), nonhigh-density lipoprotein cholesterol (non-HDL-C), and apolipoprotein B (Apo B) in patients with primary hyperlipidemia, alone or in combination with HMG-CoA reductase inhibitor; to reduce elevated total-C, LDL-C, Apo B, and non-HDL-C in patients with mixed hyperlipidemia, in combination with fenofibrate; to reduce elevated total-C and LDL-C in patients with homozygous familial hypercholesterolemia, in combination with atorvastatin or simvastatin; to reduce elevated sitosterol and campesterol in patients with homozygous sitosterolemia

Adults: 10 mg/day P.O.


• Hypersensitivity to drug or its components

• Active hepatic disease or unexplained, persistent transaminase elevations (when given with a statin)

• Women who are pregnant or may become pregnant (when given with a statin)

• Breastfeeding patients (when given with a statin)


Use cautiously in:

• moderate or severe hepatic impairment (use not recommended)

• skeletal muscle toxicity

• concurrent use of cyclosporine or fibrates other than fenofibrate (use not recommended)

• elderly patients

• pregnant or breastfeeding patients not receiving HMG-CoA reductase inhibitors

• children younger than age 10.


• Give with or without food.

• Be aware that drug may be given concurrently with HMG-CoA reductase inhibitor (such as atorvastatin or simvastatin).

• Give at least 2 hours before or 4 hours after bile acid sequestrant (if prescribed).

Adverse reactions

CNS: headache, dizziness, fatigue

EENT: nasopharyngitis, sinusitis

GI: diarrhea

Musculoskeletal: back pain, myalgia, joint pain, extremity pain, rhabdomyolysis

Respiratory: upper respiratory tract infection


Drug-drug. Cholestyramine: decreased ezetimibe blood level

Cyclosporine, fenofibrate, gemfibrozil: increased ezetimibe blood level

Fibrates: increased risk of cholesterol excretion into gallbladder leading to cholelithiasis

Drug-diagnostic tests. Liver function tests: increased values

Patient monitoring

• Monitor hepatic and lipid profiles.

• Monitor cyclosporine concentration in patients receiving drug concurrently with cyclosporine.

• Monitor International Normalized Ratio if patient also receiving warfarin.

• Assess for and report unexplained muscle pain.

• If cholelithiasis is suspected in patient also receiving fenofibrate, obtain gallbladder studies and consider alternative lipid-lowering therapy.

Patient teaching

• Teach patient about the role of diet, exercise, and weight loss in lowering cholesterol levels.

Instruct patient to immediately report unexplained muscle pain, tenderness, or weakness while taking this drug.

• Advise breastfeeding patient not to take this drug while taking a statin.

• Advise female patient of childbearing age to use effective contraception while taking this drug concurrently with a statin and if she becomes pregnant to stop taking ezetimibe and statin and call her prescriber.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.


McGraw-Hill Nurse's Drug Handbook, 7th Ed. Copyright © 2013 by The McGraw-Hill Companies, Inc. All rights reserved


A drug that inhibits the absorption of cholesterol from the intestine and is used to treat primary hypercholesterolemia.
The American Heritage® Medical Dictionary Copyright © 2007, 2004 by Houghton Mifflin Company. Published by Houghton Mifflin Company. All rights reserved.


A cholesterol absorption inhibitor drug that can be used alone or, more effectively, in conjunction with a statin drug (see STATINS) to reduce blood cholesterol levels in people with hypercholesterolaemia. Such people are at risk of developing ATHEROSCLEROSIS. The drug acts specifically to inhibit cholesterol absorption and does not affect the absorption of other lipids. A brand name is Ezetrol.
Collins Dictionary of Medicine © Robert M. Youngson 2004, 2005
References in periodicals archive ?
* If patient is unable to achieve 50% reduction in LDL-C and/or have an LDL-C level of 100 mg/dL, the addition of ezetimibe therapy is reasonable.
This drug looks safe and very effective at modifying LDL, about as much so as ezetimibe and maybe a little bit more," said Dr.
That being said, the Dietary Approaches to Stop Hypertension (DASH) diet has been shown to lower LDL by as much as 11 mg/ dL--nearly as much as ezetimibe. The DASH diet emphasizes fruits, vegetables, low-fat dairy, lean meats and fish, whole grains, nuts, legumes and heart-healthy fats and is low in sodium, saturated fat and sugar.
Phytosterolaemia responds well to dietary modification and ezetimibe. In view of the gravity of FH and phytosterolaemia, we recommend that plasma cholesterol and triglyceride measurements should be done before as well as after embarking on a high-fat diet, to ensure that high cardiovascular risk receives appropriate attention.
(30) to determine the mean percent change from baseline for lovastatin (10, 20, 40, and 80 mg), pravastatin (10, 20, and 40 mg), simvastatin (5, 10, 20, 40, and 80 mg), atorvastatin (10, 20, 40, and 80 mg), fluvastatin (20 and 40 mg), rosuvastatin (5, 10, 20, and 40 mg), and ezetimibe (10 mg; all daily doses).
The liver samples of the ezetimibe group showed moderate chronic diffuse liver congestion with periportal fibrosis and there was moderate intrahepatic cholestasis (40x magnification) (Figure 1(c)).
In case of ezetimibe treatment, the total chol absorption rate and thus the net daily amount of absorbed chol introduced to the liver via chylomicrons is strongly reduced and causes the hepatic chol pool to diminish strongly.
The two agents in the miscellaneous category are ezetimibe and lomitapide.
In a phase 2 trial (multicenter, randomized, placebo-controlled), conducted in adults with HeFH,the subjects received REGN727 150, 200, or 300 mg every 4 weeks, or 150 mg every 2 weeks, or placebo every 2 weeks (in addition to statin, with or without ezetimibe).
Usefulness of nutraceuticals (Armolipid Plus) vs Ezetimibe and combination in statin-intolerant patients with dyslipidaemia with coronary heart disease.
A drug called ezetimibe, marketed as Zetia, lowers LDL by inhibiting activity of the same protein.